DH

David J. Hackam

UP University Of Pittsburgh: 12 patents #38 of 1,817Top 3%
The Johns Hopkins University: 3 patents #1,071 of 4,416Top 25%
📍 Pittsburgh, PA: #576 of 7,570 inventorsTop 8%
🗺 Pennsylvania: #5,969 of 74,527 inventorsTop 9%
Overall (All Time): #375,030 of 4,157,543Top 10%
13
Patents All Time

Issued Patents All Time

Showing 1–13 of 13 patents

Patent #TitleCo-InventorsDate
11458141 Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders Peng-Cheng Lu, Chhinder P. Sodhi, Jun O. Liu 2022-10-04
11413299 Compositions and methods for treatment of inflammatory disorders Chhinder P. Sodhi, Peter Wipf 2022-08-16
10933077 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders Peter Wipf, Matthew D. Neal, Chhinder P. Sodhi 2021-03-02
10668092 Compositions and methods for treatment of inflammatory disorders Chhinder P. Sodhi, Peter Wipf 2020-06-02
10300083 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder 2019-05-28
10172848 Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease 2019-01-08
9562066 Oral therapy of necrotizing enterocolitis 2017-02-07
9549980 Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists 2017-01-24
9532999 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder 2017-01-03
9072760 TLR4 inhibitors for the treatment of human infectious and inflammatory disorders Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder 2015-07-07
8518903 Use of toll-like receptor-9 agonists 2013-08-27
8518905 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment of prevention of toll-like receptor-4-associated disorders Steven C. Gribar 2013-08-27
8188058 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders Steven C. Gribar 2012-05-29